One of the biggest obstacles to healthcare in the modern world is still the fight against cancer. The transition of promising therapeutics from the lab to the clinic frequently encounters substantial obstacles, despite the amazing advances in medical science. These obstacles lead to lengthy drug development timetables, excessive prices, and, most importantly, restricted efficacy for individual patients. This conundrum highlights the pressing need for creative fixes that can close the knowledge gap between preclinical research and individualised care.

BioReperia is a ray of hope for the biotechnology industry. Despite the alarming figures that 95% of preclinical medications fail during clinical development, BioReperia is a leader in the field, providing a revolutionary approach to oncology care and drug discovery. BioReperia, based in Linköping, Sweden, was established in 2015 and is a leading biotechnology company that is transforming personalised cancer treatment and medication development. Under the direction of a group of seasoned professionals, BioReperia is committed to expediting the drug discovery process and forecasting the best anti-cancer therapies for each and every patient.

The goal of BioReperia is to revolutionise cancer therapy by offering quick, precise, and individualised solutions. Their goal is to provide state-of-the-art technologies to oncologists and pharmaceutical companies so they may make well-informed decisions that save time and money while also improving patient outcomes.

ZTX®, a highly translational platform created to speed up drug discovery and enable precision treatment in oncology, is the key to BioReperia’s success. Throughout every phase of drug development, from target validation to patient stratification and companion diagnostics, our exclusive in-vivo model exhibits exceptional diagnostic accuracy.

With its core characteristics and capabilities, BioReperia’s unique platform ZTX® revolutionises personalised cancer treatment and drug development. ZTX® expedites drug discovery while cutting expenses and time by integrating seamlessly into preclinical and clinical pipelines. Oncologists can find individualised treatment plans based on the genetic composition of each patient by evaluating individual patient responses. Plus, BioReperia’s trials don’t need ethical approval, which speeds up data collecting and experimentation and promotes flexible decision-making. ZTX® plays an important role in the evaluation of immunotherapies and checkpoint inhibitors because of its capacity to replicate the tumour microenvironment and integrate immune cells. By utilising robots, BioReperia intends to automate imaging procedures and microinjections, expanding its capabilities and satisfying increasing demand. 

BioReperia has a growing global clientele that includes hospitals, universities, biotechnology businesses, pharmaceutical corporations, and healthcare providers. It has also successfully formed partnerships with well-known organisations like InVivoByosistems, Charles River Laboratories, Xenostart, and Xenopat.

A dynamic and accomplished management team leads BioReperia, with Dr. Anna Erkstam, the Chief Executive Officer, alongside Dr. Lasse Jensen, the Co-founder and Chief Technology Officer. Supporting them are key leaders including Marie Waldén, MSc, as Chief Business Officer, Franciele Dietrich Zagonel, PhD, as Customer Development Manager, and Gabriela Vazquez Rodriguez, PhD, as Project Manager. As well, the team includes Marie Högqvist as Lab Manager, Zaheer Ali, PhD, as Laboratory Engineer, Anna Fahlgren, PhD, as Co-founder, and Decky Tandiono, MSc, and Michael Jury, PhD, as Laboratory Engineers, collectively driving BioReperia’s vision of advancing cancer research and personalized medicine.

“We are harnessing the power of robotics which will significantly increase our capabilities and meet the growing demand for running projects. We are now training a robot to perform microinjections and another one to perform images automatically,” says Anna.

Many prestigious awards and recognitions have been bestowed upon BioReperia for their pioneering efforts, illustrating their importance in the field. A few of the accolades they have received include the Most Innovative CRO 2022 from the Healthcare & Pharmaceutical Awards, being named among the Top 12 EU Innovations of 2021 by the EU Commission, inclusion in the Top 50 Future Companies by the Tech Arena Foundation, and the esteemed SKAPA Innovation Prize bestowed upon them by the Swedish Government. Having received these accolades validates BioReperia’s commitment to innovative research and personalized medicine.

Beyond simply being a biotech business, BioReperia is a leader in developing new approaches to cancer research and care. BioReperia is leading the way in defining the future of personalised oncology with a dedication to innovation, accuracy, and quality.